secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pyxis Oncology, Inc. (PYXS)
CIK:        0001782223
Form:       8-K
Filed at:   2023-11-28T23:59:59+00:00
Accession:  0000950170-23-066245
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pyxis Oncology appoints Ken Kobayashi as Chief Medical Officer effective Nov 27, 2023
--------------------------------------------------------------------------------

- Ken Kobayashi appointed CMO effective Nov 27, 2023; will lead clinical and regulatory operations.
- Dr. Kobayashi has over 25 years of oncology drug development experience, including at Pfizer, Daiichi Sankyo, and AstraZeneca.
- Employment terms: $500k base salary, 40% target bonus; inducement grant of options for 1.25% of outstanding shares.
- Options vest over 4 years with 25% on 1st anniversary, then monthly; additional 0.25% vesting on milestones.
- Severance: 9 months base salary and health coverage if terminated without cause or for good reason.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023066245/0000950170-23-066245-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1782223/000095017023066245/pyxs-20231127.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-066245

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer